RATIONALE: In patients with chronic inflammatory lung disease, pulmonary proteases can generate neoantigens from elastin and collagen with the potential to fuel autoreactive immune responses. Antielastin peptide antibodies have been implicated in the pathogenesis of tobacco-smoke-induced emphysema. Collagen-derived peptides may also play a role. OBJECTIVES: To determine whether autoantibodies directed against elastin- and collagen-derived peptides are present in plasma from three groups of patients with chronic inflammatory lung disease compared with a nonsmoking healthy control group and to identify whether autoimmune responses to these peptides may be an important component of the disease process in these patients. METHODS: A total of 124 patients or healthy control subjects were recruited for the study (Z-A1AT deficiency, n = 20; cystic fibrosis, n = 40; chronic obstructive pulmonary disease, n = 31; healthy control, n = 33). C-reactive protein, IL-32, and antinuclear antibodies were quantified. Antielastin and anti-N-acetylated-proline-glycine-proline autoantibodies were measured by reverse ELISA. MEASUREMENTS AND MAIN RESULTS: All patients were deemed stable and noninfective on the basis of the absence of clinical or radiographic evidence of recent infection. There were no significant differences in the levels of autoantibodies or IL-32 in the patients groups compared with the healthy control subjects. CONCLUSIONS: Antielastin or anti-N-acetylated proline-glycine-proline autoantibodies are not evident in chronic inflammatory lung disease.
RATIONALE: In patients with chronic inflammatory lung disease, pulmonary proteases can generate neoantigens from elastin and collagen with the potential to fuel autoreactive immune responses. Antielastin peptide antibodies have been implicated in the pathogenesis of tobacco-smoke-induced emphysema. Collagen-derived peptides may also play a role. OBJECTIVES: To determine whether autoantibodies directed against elastin- and collagen-derived peptides are present in plasma from three groups of patients with chronic inflammatory lung disease compared with a nonsmoking healthy control group and to identify whether autoimmune responses to these peptides may be an important component of the disease process in these patients. METHODS: A total of 124 patients or healthy control subjects were recruited for the study (Z-A1AT deficiency, n = 20; cystic fibrosis, n = 40; chronic obstructive pulmonary disease, n = 31; healthy control, n = 33). C-reactive protein, IL-32, and antinuclear antibodies were quantified. Antielastin and anti-N-acetylated-proline-glycine-proline autoantibodies were measured by reverse ELISA. MEASUREMENTS AND MAIN RESULTS: All patients were deemed stable and noninfective on the basis of the absence of clinical or radiographic evidence of recent infection. There were no significant differences in the levels of autoantibodies or IL-32 in the patients groups compared with the healthy control subjects. CONCLUSIONS: Antielastin or anti-N-acetylated proline-glycine-proline autoantibodies are not evident in chronic inflammatory lung disease.
Authors: Kunal J Patel; Qi Cheng; Sarah Stephenson; D Patterson Allen; Changhai Li; Jane Kilkenny; Ryan Finnegan; Valeria Montalvo-Calero; Scott Esckilsen; Chentha Vasu; Martin Goddard; Satish N Nadig; Carl Atkinson Journal: Am J Respir Cell Mol Biol Date: 2019-06 Impact factor: 6.914
Authors: Marc A Sze; Pedro A Dimitriu; Shizu Hayashi; W Mark Elliott; John E McDonough; John V Gosselink; Joel Cooper; Don D Sin; William W Mohn; James C Hogg Journal: Am J Respir Crit Care Med Date: 2012-03-15 Impact factor: 21.405
Authors: Paul A Kirkham; Gaetano Caramori; Paolo Casolari; Alberto A Papi; Matt Edwards; Betty Shamji; Kostas Triantaphyllopoulos; Farhana Hussain; Mariona Pinart; Younis Khan; Lucy Heinemann; Laurie Stevens; Mike Yeadon; Peter J Barnes; Kian F Chung; Ian M Adcock Journal: Am J Respir Crit Care Med Date: 2011-10-01 Impact factor: 21.405
Authors: Francesca Polverino; Leen J M Seys; Ken R Bracke; Caroline A Owen Journal: Am J Physiol Lung Cell Mol Physiol Date: 2016-08-19 Impact factor: 5.464